Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
0.6700
+0.0046 (0.69%)
At close: Feb 3, 2026, 4:00 PM EST
0.7000
+0.0300 (4.48%)
After-hours: Feb 3, 2026, 5:09 PM EST

Galmed Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Net Income
-8.7-7.52-6.91-17.87-32.47-28.77
Depreciation & Amortization
-0.080.030.040.040.04
Loss (Gain) From Sale of Investments
1.681.140.030.520.08-0.44
Stock-Based Compensation
0.420.530.891.31.892.07
Other Operating Activities
0.490.61-0.31-0.040.01-0.25
Change in Accounts Receivable
-0.12-0.190.350.3-0.310.02
Change in Accounts Payable
0.33-0.57-0.68-2.31-2.181.05
Change in Other Net Operating Assets
-0.370.040.47-0.440.040.01
Operating Cash Flow
-6.28-5.88-6.14-18.5-32.89-26.29
Capital Expenditures
----0-0.01-0.04
Investment in Securities
-7-0.860.817.5711.4716.58
Other Investing Activities
-0.25-0.25---0-
Investing Cash Flow
-7.25-1.110.817.5611.4616.54
Issuance of Common Stock
8.298.796.190.0717.370.77
Financing Cash Flow
8.298.796.190.0717.370.77
Net Cash Flow
-5.241.80.85-0.87-4.06-8.98
Free Cash Flow
-6.28-5.88-6.14-18.51-32.9-26.33
Free Cash Flow Per Share
-1.96-6.32-26.59-132.48-240.78-222.72
Levered Free Cash Flow
-4.57-4.42-3.63-12.16-21.08-15.93
Unlevered Free Cash Flow
-4.19-4.04-3.63-12.16-21.08-15.93
Change in Working Capital
-0.17-0.730.13-2.45-2.451.07
Updated Nov 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q